AllSci News
EU grants SHINE marketing authorization for Ilumira lutetium-177 radiopharmaceutical precursor
SHINE Technologies has secured Centralized Marketing Authorization in Europe for Ilumira (non-carrier-added lutetium-177), granting the Wisconsin-based fusion company the regulatory clearance needed…
BeOne Medicines' zanubrutinib demonstrates superior progression-free survival in Phase III SEQUOIA CLL trial
BeOne Medicines (Nasdaq: ONC) reported 78-month follow-up data from the Phase III SEQUOIA trial at ASCO 2026, showing zanubrutinib (Brukinsa) maintained a...
Pfizer's lorlatinib achieves unprecedented seven-year progression-free survival in ALK-positive NSCLC
Pfizer (NYSE: PFE) reported seven-year follow-up data from the Phase III CROWN trial showing that 55% of previously untreated ALK-positive non-small cell...
Agios' tebapivat fails to meet advancement threshold in lower-risk myelodysplastic syndromes trial
Agios Pharmaceuticals (Nasdaq: AGIO) reported Thursday that tebapivat failed to meet its predefined advancement threshold in lower-risk myelodysplastic...
BMS posts Phase III data for mezigdomide showing 52% reduction in disease progression risk in r/r MM
Bristol Myers Squibb (NYSE: BMY) reported Phase III data from the SUCCESSOR-2 trial showing that mezigdomide combined with carfilzomib and dexamethasone cut...
Mayo Clinic Jacksonville backed with USD 1.87m NIH grant for PINK1 kinase Parkinson's research
Mayo Clinic Jacksonville has received a USD 1.87 million NIH RF1 grant from the National Institute of Neurological Disorders and Stroke to investigate...
Ratio Therapeutics expands PharmaLogic manufacturing collaboration for Ac-225RTX-2358 alpha therapy
Ratio Therapeutics has expanded its manufacturing collaboration with radiopharmaceutical CDMO PharmaLogic Holdings Corp. to scale clinical supply of...
Pfizer licenses USD 650m upfront Innovent oncology portfolio in USD 10.5b deal
Pfizer has committed USD 650 million upfront to license a portfolio of 12 early-stage oncology programs from Innovent Biologics (HKEX: 01801), in a deal...
FDA extends review of Beren Therapeutics' adrabetadex for infantile-onset Niemann-Pick disease type C
Beren Therapeutics has announced that the US FDA has extended by three months its review of the New Drug Application (NDA) for adrabetadex...
TG Therapeutics' ublituximab-xiiy meets primary endpoint in Phase IIIb relapsing multiple sclerosis trial
TG Therapeutics (Nasdaq: TGTX) reported that its Phase III ENHANCE trial met its primary endpoint, demonstrating that a consolidated single 600 mg infusion...
Reprogram Biosciences closes USD 6m seed round for intratumoral mRNA reprogramming platform
Reprogram Biosciences, a preclinical oncology company based in San Carlos, California, has closed a seed financing round that brings total capital raised to...
Secretome raises USD 30m Series A to advance cell therapy for Duchenne cardiomyopathy
Secretome Therapeutics, a clinical-stage biotechnology company based in Plano, Texas, has closed a USD 30 million Series A financing round to advance…
Cogent files KIT-targeted bezuclastinib + Sutent for post-imatinib GIST with FDA priority review
Cogent Biosciences (Nasdaq: COGT), based in Waltham, Massachusetts, has submitted a New Drug Application (NDA) to the US FDA for bezuclastinib in…
Palvella receives Yale-licensed patent covering topical statins for porokeratosis through 2043
Palvella Therapeutics (Nasdaq: PVLA), based in Wayne, Pennsylvania, has received US Patent No. 12,636,273 from the United States Patent and Trademark Office,…
AbbVie’s CD123 ADC Decnupaz gets FDA nod in rare blood cancer BPDCN
AbbVie (NYSE: ABBV) has received US FDA approval for Decnupaz (pivekimab sunirine-pvzy), an antibody-drug conjugate (ADC) targeting CD123, for the treatment of…
The AllSci Brief
Systematic R&D and deal news. Daily.